Post

Otsuka and Lundbeck report data from three PTSD treatment trials

Otsuka Pharmaceutical Development & Commercialization and Lundbeck Pharmaceuticals have reported results from three clinical trials evaluating the combination of brexpiprazole …

Merck’s Keytruda shows survival benefits in Phase III TNBC trial

Merck & Co (MSD) has reported that its Phase III KEYNOTE-522 clinical trial of Keytruda to treat high-risk, early-stage, triple-negative …

Advantages of decentralised trials and sites offset potential drawbacks

While the Covid-19 pandemic spurred the rise of decentralised clinical trials (DCT), the patient-centric elements of this trial model are …

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

A GlobalData conducted in 2023 found that, according to 100 healthcare industry professionals, genomics was regarded as the most potentially …

Breyanzi battles CAR-T rivals with back-to-back approvals in lymphoma

On 15 May 2024, Bristol Myers Squibb (BMS) announced accelerated FDA approval of its agent Breyanzi (lisocabtagene maraleucel) for adults …